Tamoxifen response in breast cancer predicted by protein marker
the ONA take:
An abnormally low amount of the protein TGFBR2 is associated with resistance to tamoxifen response in breast cancer treatment, according to a study published in Cancer Research.
“Our data indicate that TGFBR2, which detects TGF-beta and thereby activates subsequent cellular responses, could be used as a marker in the clinics to identify patient subgroups that may not benefit from hormone therapy alone and may require additional therapies,” said author Susann Busch, PhD, of Gothenburg University.
Dr. Busch and colleagues analyzed tumor samples of 564 pre-menopausal women who were enrolled in clinical trials from 1986 to 1991 and randomly assigned to either tamoxifen for two years (276) or no systemic treatment (288).
They found that among women who received tamoxifen and had estrogen receptor-positive tumors, those who had low TGFBR2 levels had a 73 percent lower recurrence-free survival rate compared to those with high levels of the protein.
In a follow-up series of laboratory experiments, the same researchers found that, in a drug-resistant cell line, there were low levels of TGFBR2 and abnormal pathway activation.
An abnormally low amount of the protein TGFBR2 is associated with resistance to tamoxifen response in breast cancer treatment.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|